JP2023512501A5 - - Google Patents

Info

Publication number
JP2023512501A5
JP2023512501A5 JP2022544188A JP2022544188A JP2023512501A5 JP 2023512501 A5 JP2023512501 A5 JP 2023512501A5 JP 2022544188 A JP2022544188 A JP 2022544188A JP 2022544188 A JP2022544188 A JP 2022544188A JP 2023512501 A5 JP2023512501 A5 JP 2023512501A5
Authority
JP
Japan
Prior art keywords
formula
val
compound according
cit
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022544188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512501A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/051263 external-priority patent/WO2021148501A1/en
Publication of JP2023512501A publication Critical patent/JP2023512501A/ja
Publication of JP2023512501A5 publication Critical patent/JP2023512501A5/ja
Withdrawn legal-status Critical Current

Links

JP2022544188A 2020-01-22 2021-01-21 化合物及びその複合体 Withdrawn JP2023512501A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062964180P 2020-01-22 2020-01-22
US62/964,180 2020-01-22
US202063085414P 2020-09-30 2020-09-30
US63/085,414 2020-09-30
PCT/EP2021/051263 WO2021148501A1 (en) 2020-01-22 2021-01-21 Compounds and conjugates thereof

Publications (2)

Publication Number Publication Date
JP2023512501A JP2023512501A (ja) 2023-03-27
JP2023512501A5 true JP2023512501A5 (enExample) 2024-01-19

Family

ID=74418415

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022544188A Withdrawn JP2023512501A (ja) 2020-01-22 2021-01-21 化合物及びその複合体

Country Status (15)

Country Link
US (1) US20230111996A1 (enExample)
EP (1) EP4093438A1 (enExample)
JP (1) JP2023512501A (enExample)
KR (1) KR20220130191A (enExample)
CN (1) CN115052633A (enExample)
AU (1) AU2021211892A1 (enExample)
BR (1) BR112022013966A2 (enExample)
CA (1) CA3167373A1 (enExample)
CO (1) CO2022011178A2 (enExample)
CR (1) CR20220393A (enExample)
EC (1) ECSP22064855A (enExample)
IL (1) IL294645A (enExample)
MX (1) MX2022008997A (enExample)
TW (1) TW202140076A (enExample)
WO (1) WO2021148501A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118414339A (zh) 2021-12-16 2024-07-30 迈威(上海)生物科技股份有限公司 一种喜树碱类化合物及其偶联物
CN115160403B (zh) * 2022-07-05 2025-06-27 博石丰生命科技(南通)有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法
KR20250049568A (ko) 2022-07-15 2025-04-11 페온 테라퓨틱스 리미티드 Cdcp1에 결합하는 항체 약물 접합체 및 이의 용도
EP4309676A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
WO2024051762A1 (en) * 2022-09-07 2024-03-14 Xadcera Biopharmaceutical (Suzhou) Co., Ltd. Anti-trop2/egfr antibodies and uses thereof
IL322897A (en) * 2023-02-23 2025-10-01 Phrontline Biopharma Hangzhou Co Ltd Camptothecin derivatives and conjugates, methods for their preparation and medical uses
IL324453A (en) * 2023-05-12 2026-01-01 Biocytogen Pharmaceuticals Beijing Co Ltd Binding agent compounds and ligand-drug conjugates, methods of preparation and uses thereof
EP4721767A1 (en) 2023-06-05 2026-04-08 Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. Anti-b7-h3 antibody or fragment thereof, and antibody drug conjugate targeting b7-h3
TW202540115A (zh) * 2023-11-16 2025-10-16 大陸商上海齊魯製藥研究中心有限公司 一種氘代喜樹鹼化合物及其製備和應用
CN122374343A (zh) 2023-11-30 2026-07-10 江苏康宁杰瑞生物制药有限公司 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途
AU2024415931A1 (en) 2023-12-27 2026-07-16 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Multi-specific antibody targeting her3 and trop2 and conjugate thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2026039718A1 (en) * 2024-08-16 2026-02-19 Natural State Science, Llc Cancer treatment using 5,6-dihydro-4h-benzo[de] quinoline-camptothecin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43354A (fr) * 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20190367605A1 (en) 2016-11-10 2019-12-05 Medimmune, Llc Binding Molecules Specific For ASCT2 And Uses Thereof
KR20240104214A (ko) * 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
CN116829592A (zh) * 2020-09-11 2023-09-29 免疫医疗有限公司 治疗性b7-h4结合分子

Similar Documents

Publication Publication Date Title
JP2022528851A5 (enExample)
JP7447183B2 (ja) 親水性抗体-薬物コンジュゲート
CN111295389B (zh) 生物活性物偶联物及其制备方法和用途
KR102914483B1 (ko) 가교-결합된 피롤로벤조다이아제핀 이량체(pbd) 유도체 및 이의 접합체
CA3142960C (en) A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
CN109912683B (zh) 一种细胞毒素分子、偶联物及其制备方法和应用
IL323631A (en) Compositions containing, methods and uses of antibody-TLR agonist conjugates
CN115443134A (zh) 细胞结合分子与喜树碱类似物的偶联物
CA2944699C (en) Affinity medicant conjugates
JP2022520792A5 (enExample)
JP6957629B2 (ja) 非線状自壊性リンカーおよびそのコンジュゲート
US10285955B2 (en) Affinity medicant conjugate
JP2023511184A5 (enExample)
JP2002060351A (ja) 水酸基を有する薬物を含むdds化合物
JP2003501479A (ja) 薬 剤
JP7356677B2 (ja) 複合体
JP2022514348A (ja) チオール多重リンカーを有するadc
JP2021534162A (ja) 癌を処置する方法に用いられるコンジュゲート
JPWO2019244954A1 (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン10薬剤
US12280021B2 (en) Affinity medicant conjugate
JP2009536963A (ja) ポリエチレングリコール−インターフェロンα結合体
EP4595979A1 (en) Auristatin drug with high-stability hydrophilic linking unit and conjugate thereof
US20250241872A1 (en) Affinity medicant conjugate
JP2023517477A (ja) デュオカルマイシン誘導体含有抗体薬物複合体及びチオ硫酸類を含む組合せ
WO2015192052A1 (en) Egfr targeting compounds and methods of use thereof